MCID: CLL014
MIFTS: 45

Cll/sll

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Cll/sll

MalaCards integrated aliases for Cll/sll:

Name: Cll/sll 12 15
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:6354
NCIt 50 C27911
UMLS 73 C1302547

Summaries for Cll/sll

Disease Ontology : 12 A chronic lymphocytic leukemia that is characterized by the presence of immature lymphocytes in the blood and bone marrow and/or in the lymph nodes.

MalaCards based summary : Cll/sll, also known as chronic lymphocytic leukemia/small lymphocytic lymphoma, is related to lymphoma, hodgkin, classic and diffuse large b-cell lymphoma, and has symptoms including fatigue An important gene associated with Cll/sll is ZAP70 (Zeta Chain Of T Cell Receptor Associated Protein Kinase 70), and among its related pathways/superpathways are Human T-cell leukemia virus 1 infection and DNA Damage Response. The drugs rituximab and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Decreased TP53 mRNA expression and cellular

Related Diseases for Cll/sll

Diseases related to Cll/sll via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 30.2 CD5 MME PAX5
2 diffuse large b-cell lymphoma 30.2 CD5 MME TP53
3 leukemia, chronic lymphocytic 30.1 ATM CCND1 CD38 CD5 PAX5 TP53
4 composite lymphoma 30.0 CD5 PAX5 SOX11
5 richter's syndrome 29.9 ATM CD38 CD5 TP53
6 lymphocytic leukemia 29.9 ATM CD38 CD5 MME PAX5 TP53
7 marginal zone b-cell lymphoma 29.9 CCND1 CD5 MME
8 b-cell lymphomas 29.9 CCND1 CD5 MME PAX5 TP53
9 mantle cell lymphoma 29.1 ATM CCND1 CD5 MME PAX5 SOX11
10 lymphoma, non-hodgkin, familial 28.9 ATM CCND1 CD38 CD5 MME PAX5
11 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.4
12 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.4
13 leukemia, chronic lymphocytic 2 10.7
14 leukemia, b-cell, chronic 10.7
15 leukemia 10.7
16 lymphoma 10.6
17 sarcoma 10.3
18 lymphadenitis 10.3
19 follicular lymphoma 10.2
20 peripheral t-cell lymphoma 10.2
21 diarrhea 10.2
22 melanoma 10.2
23 herpes simplex 10.2
24 lymphomatoid papulosis 10.2
25 cd45 deficiency 10.2 CD5 ZAP70
26 myxosarcoma 10.2 ATM TP53
27 necrotizing sialometaplasia 10.2 CD5 TP53
28 non-proliferative fibrocystic change of the breast 10.2 CCND1 TP53
29 verrucous carcinoma 10.1 CCND1 TP53
30 hidradenocarcinoma 10.1 CCND1 TP53
31 mutagen sensitivity 10.1 CCND1 TP53
32 waldenstroem's macroglobulinemia 10.1 CD38 CD5
33 pre-malignant neoplasm 10.1 CCND1 TP53
34 keratocystic odontogenic tumor 10.1 CCND1 TP53
35 anemia, autoimmune hemolytic 10.1
36 neutrophilic dermatosis, acute febrile 10.1
37 endometrial cancer 10.1
38 arthritis 10.1
39 glomerulonephritis 10.1
40 hemolytic anemia 10.1
41 cutaneous t cell lymphoma 10.1
42 interstitial nephritis 10.1
43 constrictive pericarditis 10.1
44 pancytopenia 10.1
45 crescentic glomerulonephritis 10.1
46 squamous cell carcinoma 10.1
47 pericarditis 10.1
48 hairy cell leukemia 10.1
49 papillary carcinoma 10.1
50 thymoma 10.1

Graphical network of the top 20 diseases related to Cll/sll:



Diseases related to Cll/sll

Symptoms & Phenotypes for Cll/sll

UMLS symptoms related to Cll/sll:


fatigue

GenomeRNAi Phenotypes related to Cll/sll according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased TP53 mRNA expression GR00389-S-5 8.62 ATM TP53

MGI Mouse Phenotypes related to Cll/sll:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.91 ATM CCND1 CD38 PAX5 SOX11 TP53
2 hematopoietic system MP:0005397 9.86 ATM CCND1 CD38 CD5 PAX5 SOX11
3 immune system MP:0005387 9.81 ATM CCND1 CD38 CD5 MME PAX5
4 endocrine/exocrine gland MP:0005379 9.8 ATM CCND1 CD38 SOX11 TP53 ZAP70
5 integument MP:0010771 9.5 ATM CCND1 CD5 MME SOX11 TP53
6 normal MP:0002873 9.1 CCND1 CD5 PAX5 SOX11 TP53 ZAP70

Drugs & Therapeutics for Cll/sll

Drugs for Cll/sll (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
2
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1 75607-67-9, 21679-14-1 30751
3
Ofatumumab Approved Phase 3,Phase 1,Phase 2 679818-59-8 6918251
4
Tenofovir Experimental, Investigational Phase 3 147127-20-6 464205
5 Antirheumatic Agents Phase 3,Phase 2,Phase 1
6 Immunologic Factors Phase 3,Phase 2,Phase 1
7 Alkylating Agents Phase 3,Phase 2,Phase 1
8 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
9 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
10 Antimetabolites Phase 2, Phase 3,Phase 1
11 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
12 tyrosine Phase 3,Phase 1,Phase 2
13 Bendamustine Hydrochloride Phase 3,Phase 2,Phase 1
14 Antiviral Agents Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 3,Phase 2,Phase 1
16 Anti-HIV Agents Phase 3,Phase 1
17 Anti-Retroviral Agents Phase 3,Phase 1
18 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
19 Antibodies Phase 3,Phase 1,Phase 2
20 Immunoglobulins Phase 3,Phase 1,Phase 2
21 Reverse Transcriptase Inhibitors Phase 3
22 Nucleic Acid Synthesis Inhibitors Phase 3
23
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907
24
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 32326 21704
25
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
26
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
27
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
28
alemtuzumab Approved, Investigational Phase 2 216503-57-0
29
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
30
Venetoclax Approved, Investigational Phase 1, Phase 2,Phase 2 1257044-40-8 49846579
31
leucovorin Approved Phase 1, Phase 2 58-05-9 6006 143
32
Pyrimethamine Approved, Investigational, Vet_approved Phase 1, Phase 2 58-14-0 4993
33
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
34
Allopurinol Approved Phase 2 315-30-0 2094
35
Nivolumab Approved Phase 2,Phase 1 946414-94-4
36
Mycophenolic acid Approved Phase 2 24280-93-1 446541
37
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
38
Melphalan Approved Phase 2 148-82-3 4053 460612
39
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
40
Idelalisib Approved Phase 2 870281-82-6
41
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
42
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
43
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
44
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
45
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
46
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 11103-57-4, 68-26-8 445354
49
motexafin gadolinium Investigational Phase 1, Phase 2 156436-89-4 12047567
50
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7

Interventional clinical trials:

(show top 50) (show all 94)
# Name Status NCT ID Phase Drugs
1 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
2 A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL Recruiting NCT03336333 Phase 3 BGB-3111;Bendamustine;Rituximab
3 Tenofovir to Prevent HBV Reactivation Recruiting NCT02186574 Phase 3 Tenofovir disoproxil;Placebo Oral Tablet
4 A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) Active, not recruiting NCT02004522 Phase 3 Duvelisib;Ofatumumab
5 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07 Enrolling by invitation NCT02049515 Phase 3 IPI-145 (duvelisib);Ofatumumab
6 Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies Terminated NCT00714259 Phase 2, Phase 3 Fludarabine
7 Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Unknown status NCT02337829 Phase 2 acalabrutinib;acalabrutinib
8 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis Completed NCT00001586 Phase 2 Fludarabine phosphate
9 Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed NCT00974233 Phase 2 Bendamustine;Rituximab;Lenalidomide
10 Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Completed NCT01515176 Phase 1, Phase 2 Dinaciclib
11 Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01002755 Phase 2 Lenalidomide
12 A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia Completed NCT01403636 Phase 2 SAR245409
13 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00280241 Phase 2 Fludarabine;Cyclophosphamide;Rituximab
14 Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00193518 Phase 2 Arsenic Trioxide
15 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Completed NCT01217749 Phase 1, Phase 2 PCI-32765;ofatumumab
16 Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Completed NCT00201682 Phase 1, Phase 2 Etanercept;Rituximab
17 Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT00193466 Phase 2 Rituximab;Fludarabine;CAMPTH-1H
18 Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00439231 Phase 2 Lenalidomide
19 Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT00290004 Phase 1, Phase 2 motexafin gadolinium
20 A Study to Investigate ICP-022 in Chinese Patients With CLL/ SLL Recruiting NCT03493217 Phase 1, Phase 2 ICP-022
21 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Recruiting NCT03740529 Phase 1, Phase 2 LOXO-305
22 Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting NCT02225275 Phase 2 Lenalidomide;Obinutuzumab
23 Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL Recruiting NCT03379051 Phase 1, Phase 2 Venetoclax;Umbralisib;Ublituximab
24 A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting NCT02514083 Phase 2 Ibrutinib;Fludarabine
25 Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NCT01066663 Phase 1, Phase 2 pyrimethamine
26 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NCT03204188 Phase 2 Ibrutinib;Fludarabine;Pembrolizumab
27 Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL Recruiting NCT01754857 Phase 2 Bendamustine;Rituximab;Lenalidomide
28 Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Recruiting NCT03010358 Phase 1, Phase 2 Entospletinib
29 Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting NCT03516617 Phase 2 Acalabrutinib
30 Safety, PK, PD, and Antitumor Activity of SNS-062 (Vecabrutinib) in B Lymphoid Cancers Recruiting NCT03037645 Phase 1, Phase 2 SNS-062
31 Phase 1/2A Dose Escalation Study in CLL, SLL or NHL Recruiting NCT01994382 Phase 1, Phase 2 Cerdulatinib (PRT062070)
32 Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Recruiting NCT03045328 Phase 2 Ibrutinib;Venetoclax
33 Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Recruiting NCT03041636 Phase 2 Ruxolitinib
34 Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) Recruiting NCT03128879 Phase 2 Venetoclax;Ibrutinib;Allopurinol
35 Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Recruiting NCT02420912 Phase 2 Nivolumab;Ibrutinib
36 HEPLISAV-B Hepatitis B Vaccine in Treatment Na(SqrRoot) ve Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton s-Tyrosine Kinase Inhibitor (BTK-I)<TAB> Recruiting NCT03685708 Phase 2
37 Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Recruiting NCT02988466 Phase 2 GVHD Prophylaxis
38 A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL Active, not recruiting NCT02135133 Phase 2 Idelalisib;Ofatumumab
39 Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Active, not recruiting NCT01497496 Phase 2 High Dose Methylprednisolone (HDMP);Ofatumumab;Lenalidomide
40 Study to Evaluate Safety and Preliminary Efficacy of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS) Active, not recruiting NCT02639910 Phase 2 Idelalisib;Venetoclax
41 Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Active, not recruiting NCT01496976 Phase 2 High Dose Methylprednisolone (HDMP);Ofatumumab;Lenalidomide
42 Efficacy and Safety of BGB-3111 in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Active, not recruiting NCT03206918 Phase 2 BGB-3111
43 Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT02518555 Phase 2 Ibrutinib
44 Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT01351896 Phase 2 Lenalidomide
45 A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Active, not recruiting NCT01145209 Phase 2 Fludarabine Phosphate;Cyclophosphamide
46 Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Active, not recruiting NCT02005289 Phase 2 lenalidomide
47 PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT01500733 Phase 2 PCI 32765
48 Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Active, not recruiting NCT01109069 Phase 2 PCI-32765
49 PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia Active, not recruiting NCT01589302 Phase 2 ibrutinib
50 Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Active, not recruiting NCT01243190 Phase 2 Ofatumumab

Search NIH Clinical Center for Cll/sll

Genetic Tests for Cll/sll

Anatomical Context for Cll/sll

MalaCards organs/tissues related to Cll/sll:

41
B Cells, Bone, Bone Marrow, Lymph Node, T Cells, Myeloid, Breast

Publications for Cll/sll

Articles related to Cll/sll:

(show top 50) (show all 144)
# Title Authors Year
1
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
2
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness. ( 29762141 )
2018
3
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. ( 29444501 )
2018
4
Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study. ( 29289901 )
2018
5
EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes. ( 30031020 )
2018
6
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. ( 30287523 )
2018
7
Pericardial Involvement with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case of Constrictive Pericarditis. ( 30140781 )
2018
8
Blood and Guts: Diarrhea from Colonic Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 30155841 )
2018
9
An Unusual Coexistence of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with Endometrioid-Type Endometrial Cancer in a 58-Year-Old Woman: A Case Study with Literature Review. ( 29928215 )
2018
10
Hypercalcemia and osteolytic bone lesions as the major symptoms in a chronic lymphocytic leukemia/small lymphocytic lymphoma patient: a rare case. ( 30416172 )
2018
11
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 30315239 )
2018
12
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. ( 30061088 )
2018
13
Lymphomatoid papulosis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: case report and literature review. ( 30142733 )
2018
14
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 30249389 )
2018
15
A Rare Case of Composite Dural Extranodal Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 29740389 )
2018
16
Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 29170253 )
2018
17
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. ( 29295653 )
2018
18
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature. ( 28714377 )
2018
19
Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 28109040 )
2018
20
CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 27221715 )
2018
21
Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting simultaneously with acquired hemophilia and warm autoimmune hemolytic anemia. ( 28670081 )
2017
22
Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in a Warthin Tumor: Case Report and Literature Review. ( 28978260 )
2017
23
An unusual case of chronic diarrhea: chronic lymphocytic leukemia/small lymphocytic lymphoma with colorectal involvement. ( 28511955 )
2017
24
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. ( 28103725 )
2017
25
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. ( 28592889 )
2017
26
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28073846 )
2017
27
Two Distinct BCL2 Rearrangements, Each Observed in 2 Independent Subclones, Evolving from a Founder Clone with Trisomy 12 in a Unique Case of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28514780 )
2017
28
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. ( 28373262 )
2017
29
Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length. ( 28718694 )
2017
30
Comparison of chromosomal rearrangements in bone marrow cells and blast transformed B-cells in relapse of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 29483496 )
2017
31
Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28802891 )
2017
32
Feasibility of Counting Smudge Cells as Lymphocytes in Differential Leukocyte Counts Performed on Blood Smears of Patients With Established or Suspected Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28371883 )
2017
33
An unusual case of chronic lymphocytic leukemia/small lymphocytic lymphoma with nodular morphology. ( 27919167 )
2017
34
CLL/SLL with initial presentation as a longstanding cutaneous plaque: A rare case. ( 27147484 )
2016
35
Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K). ( 26740820 )
2016
36
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 27324214 )
2016
37
Proliferation centers in bone marrows involved by chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic analysis. ( 27806839 )
2016
38
A novel way to consolidate incomplete responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 26390065 )
2016
39
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study. ( 26699397 )
2016
40
A Man With Chronic Lymphocytic Leukemia and Declining Kidney Function. Native kidney BK nephropathy and chronic lymphocytic leukemia/small lymphocytic lymphoma infiltration with chronic tubulointerstitial damage resulting in worsening kidney function. ( 26708199 )
2016
41
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 26764527 )
2016
42
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 27081879 )
2016
43
Bilateral Tonsillar Enlargement as a First Manifestation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with an Unusual Interfollicular Pattern of Infiltration. ( 27408379 )
2016
44
Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 27414262 )
2016
45
Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 25795422 )
2015
46
Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma. ( 25120048 )
2015
47
Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication. ( 24738974 )
2015
48
Flow cytometric analysis of lymphoid enhancer-binding factor 1 in diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma. ( 25596247 )
2015
49
The spectrum of kidney pathology in B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma: a 25-year multicenter experience. ( 25811382 )
2015
50
Collision tumor of primary merkel cell carcinoma and chronic lymphocytic leukemia/small lymphocytic lymphoma, diagnosed on ultrasound-guided fine-needle aspiration biopsy: a unique case report and review of literature. ( 24610800 )
2015

Variations for Cll/sll

Expression for Cll/sll

Search GEO for disease gene expression data for Cll/sll.

Pathways for Cll/sll

Pathways related to Cll/sll according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1 12.17 ATM CCND1 TP53
2
Show member pathways
12.12 ATM CCND1 TP53
3 12.1 ATM CCND1 TP53
4
Show member pathways
12.08 ATM CCND1 TP53
5 11.98 ATM PAX5 TP53
6
Show member pathways
11.96 ATM CCND1 TP53
7 11.86 ATM CCND1 TP53
8 11.82 ATM CCND1 TP53
9 11.64 CD38 CD5 MME
10 11.6 ATM CCND1 TP53
11 11.48 CD38 CD5 MME
12 11.3 ATM TP53 ZAP70
13 11.13 ATM CCND1 TP53
14 11.01 ATM TP53
15 10.98 ATM CCND1 TP53
16
Show member pathways
10.84 ATM TP53
17 10.71 ATM TP53
18 10.65 CD38 CD5 MME PAX5
19 10.64 ATM CCND1 TP53

GO Terms for Cll/sll

Biological processes related to Cll/sll according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to gamma radiation GO:0071480 9.16 ATM TP53
2 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
3 replicative senescence GO:0090399 8.8 ATM MME TP53

Sources for Cll/sll

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....